Top Cancer Drug Companies (2026 Update): Leaders by Revenue, Pipeline, and Growth
Reviewed by: OneDayAdvisor Editorial Team Last Updated: April 2026 The global oncology market is entering a new phase in 2026—defined by immunotherapy dominance, CAR-T expansion, and next-gen targeted therapies . While legacy giants still dominate revenue, earnings reports from Q1 2026 show a clear shift toward innovation-driven growth and aggressive M&A activity . This updated ranking incorporates: Latest Q1 2026 earnings data Oncology revenue trends Pipeline strength and strategic positioning Competitive threats (patent cliffs, biosimilars) Related: Latest Breakthroughs in Cancer Treatment In This Article: Merck (MRK) Bristol Myers Squibb Johnson & Johnson AstraZeneca Roche Novartis Eli Lilly (LLY) AbbVie Astellas Celgene 1. Merck & Co. Merck (MRK) reported strong Q4 2025 results on Feb 3, 2026, with revenue of $16.4 billion (5% increase year-over-year) and adjusted EPS o...